Trials / Completed

CompletedNCT02963896

Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma

Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma With Pretreatment Prehabituation by Chemical Vestibular Ablation

Status: Completed
Phase: N/A
Study type: Interventional
Enrollment: 20 (actual)

Sponsor: University Hospital, Motol · Academic / Other
Sex: All
Age: —
Healthy volunteers: Not accepted

Summary

Detailed description

Surgical removal of vestibular schwannoma causes acute vestibular symptoms, including postoperative vertigo and oscilopsia due to nystagmus. In general, the dominant symptom postoperatively is vertigo. Preoperative chemical vestibular ablation can reduce vestibular symptoms postoperatively. We used 1.0 ml of 40 mg/ml nonbuffered gentamicin in three intratympanic installations over 2 days, 2 months preoperatively in 10 patients. Reduction of vestibular function was measured by the head impulse test and the caloric test. Reduction of vestibular function was found in all gentamicin patient groups. After gentamicin vestibular ablation, patients underwent home vestibular exercising for two months. The control group consisted of 10 patients who underwent only home vestibular training two months preoperatively. Postoperative rate of recovery and vertigo in both groups were evaluated with the Glasgow Benefit Inventory (GBI), the Glasgow Health Status Inventory (GHSI) and the Dizziness Handicap Inventory questionnaires, as well as survey of visual symptoms by specific questionnaire developed by us.

Conditions

Vestibular Schwannoma

Interventions

Type	Name	Description
DRUG	gentamicin	intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml

Timeline

Start date: 2014-01-01
Primary completion: 2015-12-01
Completion: 2015-12-01
First posted: 2016-11-15
Last updated: 2016-11-15

Source: ClinicalTrials.gov record NCT02963896. Inclusion in this directory is not an endorsement.